Patient must not have intercurrent organ damage or medical problems that will jeopardize the outcome of therapy (i.e., psychiatric disorder, drug abuse, pregnancy)
Planning to receive other medical, surgical, or radiological cancer treatments during the course of this study
Active psychosocial condition that would hinder study compliance and follow-up
Uncontrolled angina - Canadian Cardiovascular Society grade II-IV despite medical therapy
Any serious medical condition that interferes with adherence to study procedures.
Patients with serious intercurrent infections, or nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this therapy
In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the subject's cancer.
Must have RAS mutation and microsatellite stability status results as part of medical history
Any serious medical condition that interferes with adherence to study procedures.
The patient has serious preexisting medical condition(s) that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or preexisting Crohns disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade  or higher diarrhea)
Serious cardiopulmonary medical condition
Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders that could compromise the patient's safety or the study data integrity.
Any medical condition which, in the opinion of the clinical investigator, would interfere with the evaluation of the patient; subjects with a clinically significant or unstable medical or surgical condition or any other condition that cannot be well-controlled by the allowed medications permitted in the study protocol that would preclude safe and complete study participation, as determined by medical history, physical examinations, laboratory tests, and according to the investigators judgment
Other medical or surgical conditions, especially involving the cardiac, respiratory, renal or hepatic organ systems that would either be unsafe for the patient, would limit study participation, or that would impede the determination of causality of any adverse events experienced during the conduct of this study.
Patients who, in the opinion of the principal investigator, have significant medical or psychosocial problems that warrant exclusion including:\r\n* Other serious non-malignancy-associated medical conditions that may be expected to limit life expectancy to less than  years\r\n* Any condition, medical, psychiatric or otherwise, that would preclude informed consent, consistent follow-up, or compliance with any aspect of the study
Patients whose comorbid medical condition, in the investigators opinion, would make participation in this trial and adherence to the protocol guidelines difficult should be excluded
Any other medical intervention or condition which could compromise adherence to study requirements or confound the interpretation of study results.
Medical suitability for resection, including documented medical and cardiac clearance
Inoperable on the basis of co-existent medical problems
Any other condition that in the investigators judgement would significantly increase the risks of participation.
Presence of a concomitant medical condition that (in the judgement of the investigator) interferes with the ability of the subject to participate in the study.
In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the subject's cancer.
Any coexistent medical condition interfering with drug absorption
Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study Cancer-Related Exclusion Criteria
Unstable medical comorbidities (i.e. uncontrolled cardiac comorbidities)
Medical history that includes any condition, or requires the use of concomitant medications which, in the investigator's judgment, are associated with or create a risk of increased carotid sinus sensitivity, symptomatic bradycardia, or syncopal episodes.
Any other sound medical, psychiatric, and/or social reasons as determined by the investigator
Another significant medical, psychiatric, or surgical condition which is currently uncontrolled by treatment and which would likely affect the subject's ability to complete this protocol
Patients who have major medical problems such as severe cardiac, pulmonary (COPD requiring constant oxygen), or non-healing ulceration.
A serious uncontrolled medical condition requiring therapy
Male subjects will be considered to be of non-reproductive potential if they have azoospermia (whether due to having had a vasectomy or due to an underlying medical condition)
Patient has any unstable or uncontrolled medical condition that would make it potentially unsafe to undergo TURBT including a previous stroke or myocardial infarction within  months
Ongoing severe inflammatory skin condition (as determined by the Investigator) requiring medical treatment
Medical conditions, per the investigators judgment, that predispose the patient to untoward medical risk in the event of volume loading (e.g. intravenous [IV] fluid bolus infusion), tachycardia, or hypotension during or following treatment with Pexa-Vec
Patient must have no active major medical or psychosocial problems that could be complicated by study participation
The presence of any medical condition that the Investigator deems incompatible with participation in the trial
Patients with uncontrolled serious medical condition such as persistent septicemia despite adequate antibiotic therapy, decompensated congestive heart failure despite cardiac medications or pulmonary insufficiency requiring intubation (excluding primary disease for which CB transplantation is proposed), or psychiatric condition that would limit informed consent.
Current or relevant previous history of serious, severe or unstable (acute or progressive) physical or psychiatric illness, including any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the IP or procedures.
Has known serious neuropsychiatric condition
Inoperable on the basis of co-existent medical problems
Other known other significant medical or psychiatric condition that would make assessment of toxicity or efficacy difficult
Serious concurrent medical condition including CNS disorders.
Uncontrolled serious medical condition such as persistent septicemia despite adequate antibiotic therapy, decompensated congestive heart failure despite cardiac medications or pulmonary insufficiency requiring intubation (excluding primary disease for which cord blood [CB] transplantation is proposed), or psychiatric condition that would limit informed consent
Any medical condition which, in the opinion of the clinical investigator, would interfere with the evaluation of the patient; subjects with a clinically significant or unstable medical or surgical condition or any other condition that cannot be well-controlled by the allowed medications permitted in the study protocol that would preclude safe and complete study participation, as determined by medical history, physical examinations, electrocardiogram (ECG), laboratory tests, or chest-X-ray and according to the investigators judgment
Have experienced symptomatic cardiac disease that is unresponsive to surgical or medical management
Patients with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or places them at an unacceptable risk for participation in the study
Any other ongoing serious medical problem unrelated to cancer or its treatment) that is not covered by the exclusion criteria and which is expected to significantly increase the risk of transplantation
Active, uncontrolled infection, any other concurrent disease, or medical condition that is deemed to interfere with the conduct of the study as judged by the investigator
No active major medical or psychosocial problems that could be complicated by study participation
American Urological Association (AUA) =<  with or without medical management
Life expectancy of ?  months. . Subjects with a clinically significant or unstable medical or surgical condition or any other condition that cannot be well-controlled by the allowed medications permitted in the study protocol that would preclude safe and complete study participation, as determined by medical history, physical examinations, ECG, laboratory tests or chest X-ray. Such conditions may include:  Unstable cardiovascular conditions at Baseline including but not limited to:
Major active medical or psychosocial problems that could be exacerbated by the study treatment
ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Major active medical or psychosocial problems that could be exacerbated by this treatment
Medical oncology screening evaluation performed to assess medical indication/contra-indication to vismodegib treatment
Uncontrolled medical illnesses
Patient must have no active major medical or psychosocial problems that could be complicated by study participation
Any other medical condition for which the treating physicians deem might lead to unacceptable toxicity or morbidity for that treatment plan for the patient e.g., allergy to a component of therapy or a medical condition that might be aggravated by the therapy and increases potential risk of toxicity in the opinion of the treating physicians
Patient must have no active major medical or psychosocial problems that could be complicated by study participation
Have INR > . times the institution's upper normal limit (UNL), except in subjects who are therapeutically anticoagulated for medical conditions unrelated to HCC such as atrial fibrillation. Subjects may be re-screened after condition is treated or anticoagulant is withheld.
Concurrent uncontrolled medical illness that is deemed by the investigator to have potential to interfere with the delivery of chemotherapy for a six month time period
Medical condition that would contraindicate allogeneic transplantation as per standard practice guidelines (e.g., impaired cardiopulmonary function, hepatitis, etc)
Refractory congestive heart failure unresponsive to medical treatment; active infection resistant to all antibiotics; or non-AML-associated pulmonary disease requiring > liters per minute (LPM) oxygen, or any other condition that puts the subject at an imminent risk of death.
Ongoing severe inflammatory skin condition (as determined by the Investigator) requiring medical treatment
All patients must have a surgical and medical oncology consult prior to signing informed consent
In the judgment of the investigator, participation in the protocol offers acceptable risk/benefit ratio when considering current NF disease status, medical condition, and the potential benefits of and risks of surgery or irradiation
Subjects who are deemed to be poor surgical risks by the treating neurosurgeon because of medical comorbidities
Uncontrolled medical problems
No active major medical or psychosocial problems that could be complicated by study participation
Uncontrolled medical problems
Infection or any other severe systemic disease or medical or surgical condition deemed significant by the principal investigator
Significant medical disease other than cancer
Significant medical disease other than cancer
Patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study.
Patient with any condition that the physician judges could be detrimental to subjects participating in this study; including any clinically important deviations from normal clinical laboratory values or concurrent medical events Previous treatment
Patients who, in the opinion of the principal investigator, have significant medical or psychosocial problems that warrant exclusion including:\r\n* Other serious non-malignancy-associated medical conditions that may be expected to limit life expectancy to less than  years\r\n* Any condition- medical, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study
Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect subject's safety). Subjects with isolated proteinuria resulting from MM are eligible.
Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect subject's safety). Subjects with isolated proteinuria resulting from MM are eligible, provided they fulfill criteria.
In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the subjects ALL
Concurrent medical condition that precludes safe participation in this study
Failure to demonstrate adequate compliance with medical therapy and follow-up
History of and or medical condition (e.g. diverticular disease; aneurysm) that predisposes to risk of major hemorrhage
Any serious medical condition that interferes with adherence to study procedures.
Refractory congestive heart failure unresponsive to medical treatment, active infection resistant to all antibiotics, or advanced non-MDS associated pulmonary disease requiring > liters per minute oxygen.
Any other therapy or serious medical condition, as specified in the protocol, or abnormality in clinical laboratory tests that, in the investigator's judgement, precludes the participant's safe participation in and completion of the study
No new or worsened existing acute medical condition that would require a dose hold or delay
Any medical condition that would compromise the subjects ability to safely participate in the study
No serious uncontrolled coexisting medical condition
Any acute medical problems requiring active intervention
Any coexisting medical condition precluding full compliance with the study
Considered by the investigator to be eligible for high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) according to the institution's criteria based on age, medical history, cardiac and pulmonary status, overall health and condition, co-morbid condition(s), physical examination, and laboratory studies
Patients with concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy
They have other medical problems that could get much worse with this treatment.
Poor medical risk
Subjects with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study, or places them at an unacceptable risk for participation in the study
Serious infection, immunosuppression or concurrent medical condition (chronic or acute in nature) that may prevent safe participation or ability to meet follow-up requirements
No coexisting medical problems of sufficient severity to limit compliance with the study
Has a serious concurrent medical condition such as:
have a serious illness or medical condition including, but not limited to, the following: active or uncontrolled clinically serious infection; inadequate biliary drainage with evidence of unresolved biliary obstruction
Another significant medical, psychiatric, or surgical condition which is currently uncontrolled by treatment and which would likely affect the subject's ability to complete this protocol
Subject is diagnosed with a known medical condition associated with a hypercoagulable state.
Physical abnormality or medical condition that limits swallowing multiple pills, or has a history of non-adherence to oral therapies.
No coexisting medical problems of sufficient severity to limit compliance with the study
Patient has any unstable medical condition that would make it unsafe to undergo TURBT.
Patients who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems include, but are not limited to:
Patients with concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy.
Deemed a poor surgical risk per primary medical doctor
Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the study medical monitor before study enrollment
Any medical condition that precludes the surgery necessary to administer DNX- into the tumor using the cannula
Patients who are not surgical candidates due to medical co-morbidities
Symptomatic local or regional disease requiring medical intervention
Patients with any intercurrent organ damage or medical problems that would prohibit therapy are NOT eligible for participation
Medical and/or psychiatric problems of sufficient severity to limit full compliance with the study or expose patients to undue risk
Psychiatric problems of sufficient severity to limit full compliance with the study or expose patients to undue risk
Subjects with acute medical problems such as ischemic heart or lung disease that may be considered an unacceptable anesthetic or operative risk
Medical or other condition that would represent an inappropriate risk to the patient or would likely compromise achievement of the primary study objective
Patients with any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with the completion of the study.
Medical and/or psychiatric problems of sufficient severity to limit full compliance with the study or expose patients to undue risk
Nonmalignant medical illnesses that are uncontrolled or a controlled illness that may be jeopardized by the treatment with protocol therapy
Hematological malignancy associated with a poor prognosis with medical therapy alone. Diagnoses to be included:
General medical condition: fit for the proposed surgery and/or radiation treatment as determined by the treating investigator
Serious intercurrent medical illnesses which would interfere with the ability of the patient to carry out the treatment program
Patients with grade  or greater diarrhea prior to study initiation despite maximal medical management due to medications or a medical condition such as Crohn's disease or malabsorption
Patient with other significant medical or psychiatric condition that would make assessment of toxicity or efficacy difficult
Any physical, social, or psychiatric condition that would prevent effective cooperation or participation in the study
No other serious medical condition that would interfere with follow-up
Uncontrolled serious medical condition such as persistent septicemia despite adequate antibiotic therapy, decompensated congestive heart failure despite cardiac medications or pulmonary insufficiency requiring intubation; (excluding primary disease for which cord blood [CB] transplantation is proposed), or psychiatric condition that would limit informed consent
Has an intercurrent (non-malignant) chronic medical or psychiatric illness or condition(s) not optimally controlled and carrying a moderate to high risk of interfering with protocol therapy administration or compliance with required procedures, in the judgment of the investigator
The presence of any medical condition that the Investigator deems incompatible with participation in the trial
DONOR: The presence of any medical condition that the investigator deems incompatible with participation in the trial
Medical history of orthostatic hypotension.
Any preexisting medical condition of sufficient severity to prevent full compliance with the study.
Any preexisting medical condition of sufficient severity to prevent full compliance with the study.
Uncontrolled or unstable medical or psychiatric co-morbidities which would clearly limits patients participation
Historical control data will be derived from patient medical records at the Ohio State University Medical Center (OSUMC)
History of current or prior medical problems that the investigator feels will prevent administration of therapy or assessment of response due to excess toxicity
Uncontrolled diabetes or other medical condition that may interfere with assessment of toxicity.
Subject has an existing medical condition that is likely to require repetitive MRI evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor)
Subject has an existing medical condition that is likely to require the use of diathermy in the future
Patients with acute medical condition (e.g. pneumonia, sepsis) that is expected to hinder them from completing this study
A medical condition that precludes adequate study treatment or increases patient risk
Patients with serious intercurrent infections, or nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this therapy
Patients with uncontrolled serious medical condition such as persistent septicemia despite adequate antibiotic therapy, decompensated congestive heart failure despite cardiac medications or pulmonary insufficiency requiring intubation (excluding primary disease for which CB transplantation is proposed), or psychiatric condition that would limit informed consent
Concurrent disease or condition that may interfere with study participation, or any serious medical disorder that would interfere with the subject's safety (for example, active or uncontrolled infection or any psychiatric condition prohibiting understanding or rendering of informed consent)
In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the individual's NHL
Other definitive surgical procedures may be permissible upon the approval of the medical monitor OR
Uncontrolled infection or concomitant medical illness that is not adequately controlled with current medical management, as determined per clinician discretion
Patients with >= grade  or greater diarrhea despite maximal medical management due to medications or a medical condition such as Crohn's disease, malabsorption
Unstable medical illnesses
The presence of any medical condition that the Investigator deems incompatible with participation in the trial
DONOR: The presence of any medical condition that the Investigator deems incompatible with participation in the trial
Presence of serious illnesses or medical condition(s) e.g. brain metastases, systemic infection, heart failure
Any medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study Cancer-Specific Exclusion Criteria
Patient has a major medical or co-morbid condition(s) that the investigator believes might compromise safe participation in the study (such as uncontrolled lung, kidney, or liver problems; uncontrolled infection; a history of congestive heart failure; or an electrocardiogram suggesting significant problems with the heart).
Any known preexisting medical condition that could interfere with the subject's participation in and completion of the study such as:
Any serious medical condition that places the patient at an unacceptable risk if he or she participates in this study. Examples of such a medical condition are, but are not limited to, patient with unstable cardiac disease as defined by: Cardiac events such as MI within the past  months, NYHA heart failure class III-IV, uncontrolled atrial fibrillation or hypertension; patients with conditions requiring chronic steroid or immunosuppressive treatment, such as rheumatoid arthritis, multiple sclerosis and lupus, that likely need additional steroid or immunosuppressive treatments in addition to the study treatment.
Inability to give informed consent because of psychiatric problems, or complicated medical problems.
Any other medical condition for which treatment with ipilimumab or nivolumab would be medically contraindicated
Inoperable on the basis of co-existent medical problems
Has any condition(s), which seriously compromises the subject's ability to participate in this study, sign consent, or has a known history of poor adherence with medical treatment
Presence of a severe unmanaged psychiatric condition (i.e., psychotic disorder or episode) or a psychiatric condition (e.g., suicidal intent) that would contraindicate safe participation in the study as indicated by the medical chart, treating oncologist, or interactions with the medical/study staff
Patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study.
Has another serious or chronic medical or psychiatric condition that contributes to substantial physical or emotional disability that would detract from participating in either of the intervention programs or from the measurement of intervention outcomes
Patients must not have a serious preexisting medical condition(s) or uncontrolled intercurrent illness that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade  or higher diarrhea) or psychiatric illness/social situations that would limit compliance with study requirements
Concurrent ocular or intraocular condition that requires medical or surgical intervention to prevent or treat vision loss
Medical conditions felt to be clinically contributing to fatigue based on the investigators history, physical examination, and assessment: anemia (hemoglobin less than  g/dl), hypothyroidism (thyroid stimulating hormone greater than . MCU/mL), uncontrolled pain, medical problems associated with fatigue: chronic obstructive pulmonary disease, congestive heart failure, renal disease, hepatic dysfunction, autoimmune disease, neurological disorders such as multiple sclerosis or Parkinsons disease, and poorly controlled sleep apnea
Serious underlying medical comorbidity such as uncontrolled hypertension, cardiovascular disease, pulmonary disease, psychiatric illness, or any other condition for which the patient is not approved for exercise by their physician
No medical problems for geriatric clinician to address (e.g. comorbidities, polypharmacy, etc.)
Any significant medical condition that would preclude them from exercising (e.g., congestive heart failure, angina, uncontrolled arrhythmia or other symptoms that indicate increased risk for an acute cardiovascular or respiratory event)
Presence of a severe psychiatric condition (i.e., psychotic disorder or episode) or a psychiatric condition (e.g., suicidal intent) that would contraindicate safe participation in the study as indicated by the medical chart, treating oncologist, or interactions with the medical/study staff
A prior history of any other malignancy except basal or squamous cell skin cancers, strokes, diabetes, current heart disease or uncontrolled hypertension, peripheral vascular disease, liver disease, autoimmune and/or inflammatory diseases including rheumatoid arthritis and ulcerative colitis, and other medical conditions that would limit participation in the assessments (e.g., pulmonary disease, orthopedic problems, major psychiatric illness, major cognitive dysfunction, or an acute medical problem)
A home that is deemed, upon inspection, in suitable condition to serve as a medical home, within a -minute driving distance of Duke
SUBJECT: Significant medical problems, such as severe uncontrolled illnesses, or physical impairments that prohibit the child from exercising at moderate to vigorous levels based on the clinical judgment of the examining physician or nurse practitioner.
Medical history of concussions
Presence of a severe psychiatric condition (i.e., psychotic disorder or episode) or a psychiatric condition (e.g., suicidal intent) that would contraindicate safe participation in the study as indicated by the medical chart, treating oncologist, or interactions with the medical/study staff
Unstable medical problems (such as unstable heart disease, unstable hypertension, diabetes in poor control, respiratory disease complicated by hypoxia or hypercapnia, infectious illnesses, unstable thyroid dysfunction, currently hospitalized)
For participants who are randomized in aim :\r\n* No uncontrolled serious medical or psychiatric condition(s) that would affect the patients ability to participate in the interventional study, e.g., uncontrolled hypertension, symptomatic cardiac disease, or severe/uncontrolled depression as indicated by a Patient Health Questionnaire (PHQ-) score >  (Kroenke)\r\n* No diagnoses of any other invasive malignancy other than endometrial cancer or non-melanoma skin cancer which required active treatment currently
History of a chronic medical condition that has the potential to significantly impact upper extremity function (e.g. stroke, Parkinsons disease, multiple sclerosis)
Provide consent and permission to review their medical records
Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's and/or Medical Monitor's judgment, precludes the participants safe participation in and completion of the study
Clinician believes that eradication of concomitant HSIL is reasonable and feasible based on the extent of disease and overall medical condition of the participant
Medical clearance by Dr. Murphy
Serious or unstable medical condition that could likely lead to hospitalization during the course of the study or compromise study participation
Self-report or have a medical record of an unstable comorbid medical or psychiatric condition that would make it unsafe or impossible to adhere to the study protocol
Medical conditions felt to be clinically contributing to fatigue based on the investigators history, physical examination, and assessment: anemia (hemoglobin less than  g/dl), hypothyroidism (thyroid stimulating hormone greater than . MCU/mL), uncontrolled pain, medical problems associated with fatigue: chronic obstructive pulmonary disease, congestive heart failure, renal disease, hepatic dysfunction, autoimmune disease, neurological disorders such as multiple sclerosis or Parkinsons disease, and poorly controlled sleep apnea
Medical clearance from treating clinician for study participation
No medical contra-indication for colonoscopy
Uncontrolled concurrent medical condition likely to limit compliance with the study interventions
Any other serious medical condition that would make PA unsafe
Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study
Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect subject's safety). Subjects with isolated proteinuria resulting from MM are eligible, provided they fulfil the inclusion criteria related to organ system function.
Subject has significant uncontrolled medical condition within  months prior to enrollment, as determined by the investigator.
Medical problems which may prevent them from attending  educational sessions
Individuals suffering from any unstable medical condition precluding the use of NRT (identified using the Medical History Questionnaire given at baseline)
Positive history of a medical condition that precludes use of the nicotine patch
Serious medical condition (e.g., cancer, heart disease, kidney disease, diabetes)
Any medical condition judged by the investigator to constitute a risk to safe participation
Free of obvious health problems as established by medical history and clinical examination before entering into the study.
Intercurrent illness or other major medical condition or comorbid condition that might affect study participation (uncontrolled renal, pulmonary or hepatic dysfunction or infection)
Availability of the patients medical information
Patient/participant has a medical condition which in the judgment of the investigator might make supine positioning for the duration of the scan unsafe, such as (but not limited to) congestive heart failure or significant pulmonary\r\ndisease
Medical condition which requires pre-medication prior to dental visits/procedures
Unstable medical condition, such as ischemic heart disease, or any other disease or medical condition that may place the patient at added risk during the study, as assessed by the Principal Investigator. A patient with a seizure disorder, focal or generalized, not adequately controlled by anti-convulsant therapy, and /or patient who have experienced an event of focal or generalized seizure within  days prior to screening will be considered neurologically unstable.
Medical condition uncontrolled by treatment making completion of study unlikely
Patients will be referred by the Urology or Medical Oncology Departments for participation in the study
Medical condition uncontrolled by treatment making completion of study unlikely
Patients will be screened with a questionnaire to be sure they have no medical devices that could make the procedure unsafe
GROUP : Non-oncologic patients from Veteran Affairs Medical Center (VAMC) in Houston:
Medical history, physical exam, and vital signs within  days of enrollment
Must have no known medical problems and have had a full medical exam within  months of the study
BIODISTRIBUTION COHORT: Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
DYNAMIC COHORT: Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
No unstable and significant medical conditions as determined by medical history (to ensure safety of the subject, to minimize the effects of poor health on biomarker measures and to maximize compliance to study procedures)
Patients with severe uncontrolled medical problems are not eligible for this trial.
No unstable and significant medical or psychiatric conditions, including lack of stabilization of medications, to be determined by medical history and Prime- doctor of medicine (MD) (to ensure safety of the subject, to minimize the effects of poor health on biomarker measures and to maximize compliance to study procedures)
Have a contraindication to NSAIDs at the oncologists discretion (i.e., allergy, worsening of ongoing medical problem due to NSAID, low platelet count from chemotherapy, and uncontrolled condition such as hypertension or asthma)
MEDICAL CHART REVIEW
No uncontrolled serious medical problems except for the diagnosis of cancer.
